IGF1 levels could potentially be monitored in patients with myeloproliferative neoplasms as a biomarker for nutritional intervention efficacy, particularly given that recent meta-analytic evidence demonstrates an association between IGF1 level ranges and all-cause mortality, with a specific 120–160 ng/mL range being associated with the lowest mortality. This evidence concerns the gene IGF1 and myeloproliferative disorder.